Beyang Therapeutics recently participated in the OpenADMET Blind PXR Induction Activity Prediction Challenge (Apr 1, 2026 – Jul 1, 2026). Our team placed 8th out of over 350 participants in the Challenge.

Shanghai, June 2, 2026 — Beyang Therapeutics Co., Ltd. today announced the kick-off meeting for the Phase Ib clinical trial in China for of BT01001 Ophthalmic Solution.

Shanghai, May 15, 2026 — Beyang Therapeutics Co., Ltd, a clinical-stage niopharmaceutical company pioneering next-generation targeted therapies for hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Ophan Drug Designation (ODD) to BY002, an oral, otent, and highly selective next-generation menin inhibitor.

Beyang Therapeutics Co., Ltd., a clinical-stage AI-driven biotechnology company, announced the successful completion of the Phase I trial for its investigational BT01001 ophthalmic solution in healthy subjects. The randomized, double-blind, placebo-controlled study demonstrated excellent safety and tolerability.

Beyang Therapeutics has participated in the “OpenADMET - ExpansionRx Blind Challenge” jointly organized by OpenADMET and Expansion Therapeutics (Oct 27, 2025 – Jan 19, 2026).

Shanghai, October 30, 2025 — Beyang Therapeutics Co., Ltd. today announced the initiation of its Phase I clinical trial in China for of BT01001 Ophthalmic Solution, a novel therapy to treat diabetic retinopathy (DR) through non-invasive topical administration. This milestone follows the approval of its Investigational New Drug (IND) application by the National Medical Products Administration (NMPA) in September 2025.

Shanghai, CHINA — September 11, 2025 — Beyang Therapeutics Co., Ltd., a clinical-stage AI-driven biotechnology company, today announced that China’s National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application for BT01001, a first-in-class ophthalmic solution for the treatment of diabetic retinopathy (DR).

Shanghai, CHINA — March 25, 2025 — Beyang Therapeutics Co., Ltd., a clinical-stage AI-driven biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BT01001, a first-in-class ophthalmic solution for the treatment of diabetic retinopathy (DR). The IND clearance marks a major milestone for Beyang in the development of innovative treatments for diabetic retinopathy.

Shanghai, China–February 21, 2025—Beyang Therapeutics, a clinical-stage biotechnology company dedicated to developing innovative treatments for retinal diseases, has announced today the submission of an Investigational New Drug (IND) application of BT01001, a novel ophthalmic solution for the treatment of diabetic retinopathy (DR), to the U.S. Food and Drug Administration (FDA).

Beyang Therapeutics recently presented its second-generation menin inhibitor, BTC-86, at the 66th Annual Meeting of the American Society of Hematology (ASH). BTC-86 has demonstrated remarkable advantages over the first-generation menin inhibitor, Revumenib, including overcoming resistance mutations and minimizing QTc prolongation. These breakthroughs have garnered significant attention from hematological oncologists, experts, and industry leaders worldwide.